Penserra Capital Management LLC Autolus Therapeutics PLC Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$5.1 - $7.0 $6,655 - $9,135	-1,305 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $399 - $552	75 Added 6.1%	1,305 $8,000
Q2 2021 Aug 12, 2021	BUY	$4.78 - $7.96 $2,198 - $3,661	460 Added 59.74%	1,230 $8,000
Q1 2021 May 13, 2021	SELL	$5.49 - $9.36 $137 - $234	-25 Reduced 3.14%	770 $4,000
Q4 2020 Feb 12, 2021	BUY	$8.13 - $12.79 $4,154 - $6,535	511 Added 179.93%	795 $7,000
Q3 2020 Nov 13, 2020	BUY	$11.64 - $16.3 $3,305 - $4,629	284 New	284 $3,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.